A Study of Rifabutin and MK-4646 in Healthy Participants (MK-4646-004)
Completed · Phase 1
Conditions studied: Healthy
In brief
Researchers have designed a new study medicine called MK-4646 as a new way to treat human immunodeficiency virus (HIV). Rifabutin is a medication used to treat tuberculosis (TB). Researchers want to learn about MK-4646 when taken at the same time as Rifabutin. They want to: Measure a person's blood to find out if the amount of MK-4646 in the blood is the same when MK-4646 is taken alone or with Rifabutin Learn about the safety of MK-4646 when taken alone or with Rifabutin and if people tolerate it
Key facts
- Study ID
- NCT07199452
- Run by
- Merck Sharp & Dohme LLC
- People needed
- 18
- Starts
- 2025-10-28
- Expected to finish
- 2026-01-07
- Last updated by the study team
- 2026-01-29
Who can join
Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.
Where it is running
- Fortea CRU Madison ( Site 0001) — Madison, Wisconsin, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.